Namita Joshi

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Mahmoud Elsawy, Julio C. Chávez, Irit Avivi et al. · Blood · 2022 · 75 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Relationship Between Depression and Physical Activity, Disability, Burden, and Health-Related Quality of Life Among Patients with Arthritis

Namita Joshi, Rahul Khanna, Ruchit Shah · Population Health Management · 2014 · 48 citations

Education, Health Sciences, Physical Activity +16

Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

Viktor Chirikov, Ingrid Ma, Namita Joshi et al. · Value in Health · 2018 · 32 citations · Full text

Pharmacy, Neurology, Pharmacoeconomics +17

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment

Sandy Srinivas, Ateesha F. Mohamed, Sreevalsa Appukkuttan et al. · Cancer Medicine · 2020 · 32 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Under-use of Hypomethylating Agents in Patients With Higher-risk Myelodysplastic Syndrome in the United States: A Large Population-based Analysis

Shelby Corman, Namita Joshi, Tim Wert et al. · Clinical Lymphoma Myeloma & Leukemia · 2020 · 25 citations · Full text

Medicine, Hematology, Pharmacotherapy +15